FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to medicine and pharmaceutics, namely to a method for determining whether a patient will respond to treatment of a haematological malignant growth, which is refractory to chemotherapy, using a molecule bispecific to CD123×CD3 molecules, wherein said method includes: (A) evaluating the expression of one or more target genes in a cell sample obtained from said patient relative to the expression of the set of target genes and/or one or more reference genes, and (B) identifying said patient as a patient who will respond to treatment with a therapeutically effective amount of the bispecific CD123×CD3 molecule, if it is found that expression of said one or more target genes, the expression of which is assessed, is increased compared to said expression of one or more target genes and/or reference genes, the expression of which is assessed.
EFFECT: identifying a subpopulation of patients with a refractory haematologic malignant neoplasm responding well to treatment with bispecific to CD123×CD3 binding molecules.
25 cl, 14 dwg, 12 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
| DELIVERY OF THERAPEUTIC POLYPEPTIDES VIA PSEUDOTYPED ONCOLYTIC VIRUSES | 2017 |
|
RU2758007C2 |
| HEAVY CHAIN-ONLY ANTIBODIES THAT BIND TO CD19 | 2019 |
|
RU2824170C2 |
| TREATMENT OF MALIGNANT TUMOR USING ANTI-CD19 ANTIGEN CHIMERIC RECEPTOR | 2015 |
|
RU2815417C2 |
| ANTI-TRBC1 ANTIGEN-BINDING DOMAIN | 2018 |
|
RU2791327C2 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
| IL-4/IL-13 PATHWAY INHIBITORS FOR HIGHER EFFICACY IN TREATING MALIGNANT NEOPLASMS | 2020 |
|
RU2836467C2 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
